Correlation Between 10X Genomics and Crispr Therapeutics

Can any of the company-specific risk be diversified away by investing in both 10X Genomics and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining 10X Genomics and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between 10X Genomics and Crispr Therapeutics AG, you can compare the effects of market volatilities on 10X Genomics and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in 10X Genomics with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of 10X Genomics and Crispr Therapeutics.

Diversification Opportunities for 10X Genomics and Crispr Therapeutics

0.92

Correlation Coefficient

10X Genomics  Crispr Therapeutics

Almost no diversification

The 3 months correlation between 10X and Crispr is 0.92. Overlapping area represents the amount of risk that can be diversified away by holding 10X Genomics and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and 10X Genomics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on 10X Genomics are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of 10X Genomics i.e., 10X Genomics and Crispr Therapeutics go up and down completely randomly.

Pair Corralation between 10X Genomics and Crispr Therapeutics

Considering the 90-day investment horizon 10X Genomics is expected to generate 0.94 times more return on investment than Crispr Therapeutics. However, 10X Genomics is 1.06 times less risky than Crispr Therapeutics. It trades about 0.18 of its potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.17 per unit of risk. If you would invest  861.00  in 10X Genomics on May 4, 2025 and sell it today you would earn a total of  447.00  from holding 10X Genomics or generate 51.92% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

10X Genomics  vs.  Crispr Therapeutics AG

10X Genomics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in 10X Genomics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite nearly uncertain basic indicators, 10X Genomics reported solid returns over the last few months and may actually be approaching a breakup point.

Crispr Therapeutics

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Crispr Therapeutics AG are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Crispr Therapeutics reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with 10X Genomics and Crispr Therapeutics

The main advantage of trading using opposite 10X Genomics and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if 10X Genomics position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.

The idea behind 10X Genomics and Crispr Therapeutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..